Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

Mankind Pharma completes acquisition of BSV

Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.

SIBUR to provide raw materials to Russian medical industry

SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization

India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh

We now rank 3rd in pharmaceutical production by volume and 14th by value

Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility

US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years

Biocon partners with Tabuk to commercialize its Glucagon-like peptide-1 products in the Middle East

Fasenra recommended for approval in the EU by CHMP for treatment of EGPA

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant

The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD

Zydus announces licensing and supply agreement for two Gadolinium based MRI injectable

Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market